Nanotechnology is rapidly transforming the landscape of healthcare, particularly in the management of complex chronic conditions like metabolic syndrome. While nanomaterials offer immense promise for targeted drug delivery, biosensing, and personalized interventions, their clinical application demands thorough investigation into their safety and biocompatibility. This chapter explores the biological interactions of commonly used nanomaterials—such as gold, silver, lipid-based carriers, and polymeric systems—within the unique physiological context of metabolic syndrome. Emphasis is placed on understanding how factors like oxidative stress, chronic inflammation, and altered metabolic environments influence nanoparticle behaviour and toxicity in affected individuals. Real-world case studies and in vivo models are discussed to assess hemocompatibility, immunogenicity, and organ-specific accumulation. The chapter also reviews regulatory concerns and presents practical strategies to design safer nanotherapeutics, including surface functionalization, green synthesis, and responsive delivery systems. By bridging laboratory science with clinical relevance, this chapter aims to guide researchers and clinicians toward responsible and effective integration of nanotechnology into metabolic health care.